Green Cross Holdings Corporation

Equities

A005250

KR7005250006

Pharmaceuticals

End-of-day quote Korea S.E. 06:00:00 2024-04-25 pm EDT 5-day change 1st Jan Change
15,270 KRW +0.13% Intraday chart for Green Cross Holdings Corporation +0.86% -6.61%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Green Cross Holdings Corporation Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Tiantan Biological Unit Registers Blood Disorder Treatment; Shares Jump 4% MT
Green Cross's Net Income Plunges in Q2 MT
South Korea's FTC Imposes 40.9 Billion Won in Fines on Drug Firms for Bid-Rigging MT
Feldan Therapeutics announced that it has received $16.5 million in funding from Amgen Ventures, Investissement Québec, Investment Arm, Green Cross Holdings Corporation and other investors CI
Green Cross Holdings Corporation Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Green Cross Swings to Loss in Q1 MT
Feldan Bio Inc. announced that it has received funding from Green Cross Holdings Corporation, Consortium Québécois sur la Découverte du Médicament, Centre for Commercialization of Regenerative Medicine CI
Green Cross' Net Profit Falls 27% in Q3 MT
Green Cross Holdings Corporation completed the acquisition of Highlander Factory, Inc. from New Jersey Innovation Institute Inc. CI
Green Cross' Net Income Rises 3% in March Quarter MT
Green Cross Holdings Corporation signed an agreement to acquire Highlander Factory, Inc. from New Jersey Innovation Institute Inc. for $73 million. CI
MedAdvisor Expands to New Zealand with Green Cross Health Deal MT
Green Cross Lab Cell Corporation completed the acquisition of Green Cross Cell Corporation from a group of shareholders. CI
Green Cross Lab Cell Corporation entered into a definitive merger agreement to acquire Green Cross Cell Corporation from a group of shareholders for approximately KRW 510 billion. CI
Aqua Metals : Start-ups aim to change car battery recycling, clean up world's most polluting industry RE
FACTBOX-Key facts about used lead-acid battery recycling RE
Market Chatter: Green Cross Wellbeing to Adapt Liver Drug Laennec for COVID-19 Treatment: Drug Safety Ministry MT
Artiva Biotherapeutics, Inc. announced that it has received $120.000001 million in funding from a group of investors CI
Artiva Biotherapeutics, Inc. announced that it expects to receive $120.000001 million in funding CI
EANS-News : AGRANA: Weekly rapid coronavirus tests for employees prove their worth DJ
Humanscape, Inc. announced that it has received KRW 13.1 billion in funding from Korea Investment Partners Co. Ltd., Green Cross Holdings Corporation, Nau IB Capital, Investment Arm, Carelabs Co.,Ltd, KB Securities Co., Ltd., Investment Arm CI
Green Cross : Asia offers more flu shots to head off COVID-19 complications RE
South Korea approves phase II human trial for Green Cross's coronavirus treatment drug RE
Green Cross : South Korea's Green Cross seeks phase 2 trials of COVID-19 plasma drug RE
Chart Green Cross Holdings Corporation
More charts
Green Cross Holdings Corp is a Korea-based investment holding company principally engaged in the manufacture and distribution of pharmaceuticals. The Company’s products portfolio consists of prescription drugs, blood derivatives, vaccines, cerebrovascular disease treatment, hunter syndrome drugs, as well as over the counter (OTC) drugs, such as skin disease treatment drugs, allergic cream and others. Its products are used for analgesic, treatment of cerebral thrombosis, hypoalbuminemia, genodermatosis and others, as well as prevention of influenza, prophylaxis of varicella, among others. The Company is also involved in the real estate sales and leasing, as well as construction business.
More about the company